Liminatus Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $150.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Liminatus Pharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Liminatus Pharma filed with the SEC
Liminatus Pharma Regains Compliance with Nasdaq
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Liminatus Pharma, Inc. Announces Reverse Stock
Listing notice · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Liminatus Pharma Enters Into Warrant Exercise
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Liminatus Pharma, Inc. Announces Pricing of
Material agreement · Other events · EX-99.1 to Form 8-K
IBA101: The Strategic Answer to the PD-1/L1 Patent Cliff
Regulation FD disclosure · EX-99.1 to Form 8-K
Liminatus Pharma Charts Dual-Front Attack on
Regulation FD disclosure · EX-99.1 to Form 8-K
Crafting the Future of Healing for Patients Next Generation CD47 Blockade with Liminatus Pharma, Innobation Bio
Other events · EX-99.1 to Form 8-K
Liminatus Pharma, the newest immuno-oncology entrant on Nasdaq (ticker:
Other events · EX-99.2 to Form 8-K
To the Board of Directors and Stockholder of
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
To the Board of Directors, Stockholders, and Members
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
terms included below have the same meaning as terms defined and included elsewhere in this report, unless defined below. As used in
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K